In re Application of: Niva SHAPIRA et al
Serial No.: 10/543,022
Filed: September 14, 2006
Office Action Mailing Date: February 12, 2010

Examiner: Audrea BUCKLEY
Group Art Unit: 1611
Attorney Docket: 32467
Confirmation No.: 4059

In the Claims:

1. (Currently Amended) A composition for potentiating antioxidative activities, consisting essentially of:

(a) at least one antacid component in a dose capable of elevating the pH in a stomach by at least one pH unit~~sufficient to elevate pH in a stomach~~;

(b) at least one antioxidant component, wherein the relative amount of the antioxidant in the composition is from 10 to 95% w/w of the total antacid and antioxidant weight ~~in a dose sufficient to decrease free radical generation in the stomach~~; and, optionally,

(c) at least one pharmaceutically acceptable carrier.

2.-62. (Canceled)

63. (Previously Presented) The composition according to claim 1, wherein the composition is capable of decreasing generation of free radicals and peroxides in the stomach or esophagus more than the same dose of antioxidant in an absence of antacid.

64. (Previously Presented) The composition according to claim 63, wherein the composition has an ability to decrease at least two fold concentration of free radicals and peroxides in the stomach or esophagus.

65. (Previously Presented) The composition according to claim 1, comprising at least two distinct antioxidants.

66. (Previously Presented) The composition according to claim 1, comprising at least two distinct antacids.

In re Application of: Niva SHAPIRA et al
Serial No.: 10/543,022
Filed: September 14, 2006
Office Action Mailing Date: February 12, 2010

Examiner: Audrea BUCKLEY
Group Art Unit: 1611
Attorney Docket: 32467
Confirmation No.: 4059

67. (Canceled)

68. (Previously Presented) The composition according to claim 1, wherein the antacid component comprises at least one classical antacid selected from a group consisting of: aluminum carbonate, aluminum hydroxide, aluminum phosphate, aluminum hydroxy carbonate, dihydroxy aluminum sodium carbonate, aluminum magnesium glycinate, dihydroxy aluminum aminoacetate, dihydroxyaluminum aminoacetic acid, calcium carbonate, calcium phosphate, hydrated magnesium aluminate activated sulfate, magnesium aluminate, magnesium aluminosilicates, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide and magnesium trisilicate.

69. (Withdrawn) The composition according to claim 1, wherein the antacid component comprises at least one H_2-receptor antagonist selected from a group consisting of: cimetidine, ranitidine, famotidine and nizatidine.

70. (Withdrawn) The composition according to claim 1, wherein the antacid component comprises at least one proton pump inhibitor selected from a group consisting of: omeprazole, hydroxyomeprazole, lansoprazole esomeprazole, pantoprazole and rabeprazole sodium.

71.-73. (Canceled)

74. (Previously Presented) The composition according to claim 1, wherein the antioxidant component comprises one or more ingredients selected from a group consisting of: polyphenols, buffering agents, reducing agents and plant-derived antioxidants.

In re Application of: Niva SHAPIRA et al
Serial No.: 10/543,022
Filed: September 14, 2006
Office Action Mailing Date: February 12, 2010

Examiner: Audrea BUCKLEY
Group Art Unit: 1611
Attorney Docket: 32467
Confirmation No.: 4059

75. (Previously Presented) The composition according to claim 74, wherein the antioxidant is a polyphenol selected from a group consisting of: chalcones; phenolic acid; anthocyanins; flavonol; flavanols; flavanones ; flavanonols; hydrolyzed tannins; proanthocyanidin; phenolamine; lignans; lignine; betalains; stilbenes—; cyclic diterpenes~~diuterpenes~~; monoterpenes~~mono~~ and sesquiterpenes—; sesamolin and isoflavones.

76. (Canceled)

77. (Currently Amended) The composition according to claim 1~~76~~, wherein the relative amount of the antioxidant in the composition is from ~~about~~ 20 to ~~about~~ 85% w/w of the total antacid and antioxidant weight.

78. (Currently Amended) The composition according to claim 77, wherein the relative amount of the antioxidant in the composition is from ~~about~~ 40 to ~~about~~ 60% w/w of the total antacid and antioxidant weight.

79. (Previously Presented) The composition according to claim 1, wherein the composition is provided in any physical form suitable for oral administration.

80. (Previously Presented) The composition according to claim 79, the composition having a physical form selected from a group consisting of: tablet, compressed tablet, spheroid, capsule, powder and suspension and liquid.

81. (Previously Presented) The composition according to claim 80, further comprising at least one ingredient selected from a group consisting of: filler, disintegrant, anticaking agent, film coating, coating solution, binder, stabilizer for solution or for solid forms, entericoating polymer, sweetening agent, glidant, flavor, color, lubricant and plasticizer.

In re Application of: Niva SHAPIRA et al
Serial No.: 10/543,022
Filed: September 14, 2006
Office Action Mailing Date: February 12, 2010

Examiner: Audrea BUCKLEY
Group Art Unit: 1611
Attorney Docket: 32467
Confirmation No.: 4059

82. (Withdrawn) A pharmaceutical composition, consisting essentially of:

(a) at least one pharmaceutically active ingredient;

(b) at least one antacid component in a dose sufficient to elevate pH in a stomach;

(c) at least one antioxidant component in a dose sufficient to decrease free radical generation in the stomach; and, optionally,

(d) at least one pharmaceutically acceptable carrier, diluent or stabilizer.

83. (Withdrawn) The composition according to claim 82, wherein the composition is capable of decreasing generation of free radicals and peroxides in the stomach or the esophagus more than same dose of antioxidant in an absence of antacid.

84. (Withdrawn) The composition according to claim 83, wherein the composition has an ability to decrease at least two fold concentration of free radicals and peroxides in the stomach or esophagus.

85. (Withdrawn) A method for protection from oxidative damage, comprising administering to a subject a composition consisting essentially of:

(a) at least one antacid component in a dose sufficient to elevate pH in a stomach;

(b) at least one antioxidant component in a dose sufficient to decrease free radical generation in the stomach; and, optionally

(c) at least one carrier, diluent or stabilizer.

86. (Withdrawn) The method of claim 85, wherein administering step results in inhibition of peroxidation reactions in a GI tract.

87. (Withdrawn) The method of claim 85, wherein administering step results in attenuation of generation of free radicals and peroxides in a GI tract.